Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.43 |
| ▸ | GCGR | P47871 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.42 |
| ▸ | APOB | P04114 | 3/20 | 0.41 |
| ▸ | MTTP | P55157 | 3/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493011 | 0.93 | MTTP (0.48) | TRPV1PTGS1KITAPOBMTTP | |
| SCHEMBL6501885 | 0.93 | GCGR (0.44) | GCGRKITKDR | |
| SCHEMBL6502528 | 0.92 | TRPV1 (0.42) | TRPV1GCGRPTGS1KITAPOB | |
| SCHEMBL6491523 | 0.91 | KIT (0.42) | TRPV1GCGRPTGS1KITAPOB | |
| SCHEMBL6489810 | 0.90 | P2RX1 (0.50) | TRPV1GCGRPTGS1EGLN1 | |
| SCHEMBL6499114 | 0.90 | HDAC7 (0.47) | GCGRTP53 | |
| SCHEMBL6489404 | 0.89 | LMNA (0.43) | TRPV1GCGRPTGS1KITAPOB | |
| SCHEMBL6501001 | 0.89 | OPRL1 (0.43) | TRPV1GCGRPTGS1KITAPOB | |
| SCHEMBL6499727 | 0.88 | OPRL1 (0.43) | TRPV1GCGRKITAPOBMTTP | |
| SCHEMBL6791861 | 0.88 | PTGS1 (0.51) | TRPV1PTGS1KITAPOBMTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | TRPV1 2245/4885GCGR 1784/4885PTGS1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.